Evaluating Pharmacogenomic Prescription Data in the Military Health System - PubMed
6 days ago
- #Adverse Drug Events
- #Pharmacogenomics
- #Military Health System
- Pharmacogenomic testing (PGx) is often reactive but moving to preemptive testing could reduce adverse drug events (ADEs) and improve combat readiness.
- Limited research exists on the impact of preemptive PGx testing in the Military Health System (MHS).
- A retrospective study used FY21 MHS prescription data to estimate the impact of PGx testing.
- Over 8 million prescriptions for 83 PGx-related medications were analyzed, with 15% for Active Duty and Reserve members.
- Top prescribed PGx medications for Active Duty members included ibuprofen, ondansetron, hydrocodone, omeprazole, and meloxicam.
- Up to 632,974 MHS beneficiaries taking omeprazole were predicted to have non-normal CYP2C19 metabolism.
- Allopurinol had the highest risk for severe ADEs, with up to 301 prescriptions for Active Duty members with the *58:01 variant.
- PGx testing is underutilized in MHS despite actionable guidelines, suggesting a need for preemptive testing to reduce ADEs and improve readiness.